Humacyte Publication in the Journal of Vascular Surgery Vascular Science Reports the Human Acellular Vessel Remains Durable at Six Years in Patients with Peripheral Artery Disease

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced the publication of '6-Year Outcomes of a Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass,' in the Journal of Vascular Surgery - Vascular Science. The publication describes the long-term analysis of the Company's Phase 2 clinical trial evaluating the bioengineered HAV as a conduit in patients with symptomatic peripheral …